Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01044108 · ClinicalTrials.gov registry record · Phase 1
A Two Part Trial Investigating an Anti-obesity Drug in Overweight/Obese Male and Female Healthy Volunteers
A Phase 1 study, sponsored by Novo Nordisk A/S.
- Terminated
- Registry status
- Phase 1
- Development phase
- 117
- Enrollment target
NCT01044108 is a Phase 1 study that was terminated before completion, run by Novo Nordisk A/S. The registered enrollment target is 117 participants.
The verdict
NCT01044108, a Phase 1 study, was terminated before completion, sponsored by Novo Nordisk A/S.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 117 participants
- Enrollment target
Study Summary
This trial is conducted in the United States of America (USA). The aim of this trial is to investigate the safety, tolerability, efficacy and pharmacokinetics (the rate at which the trial drug is eliminated from the body) of NNC 0070-0002-0453 in overweight/obese, but otherwise healthy male and female volunteers. Selected subjects will continue in a follow-up period of up to 5 years.
Interventions
- DRUG placebo
- DRUG NNC 0070-0002-0453
- DRUG '2-0453
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2010-01-05 |
| Est. Completion | 2011-09-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01044108
The ClinicalTrials.gov registry entry for NCT01044108 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 117 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT01044108 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01044108 about?
NCT01044108 is a clinical study titled "A Two Part Trial Investigating an Anti-obesity Drug in Overweight/Obese Male and Female Healthy Volunteers". This trial is conducted in the United States of America (USA). The aim of this trial is to investigate the safety, tolerability, efficacy and pharmacokinetics (the rate at which the trial drug is eliminated from the body) of NNC 0070-0002-0453 in overweight/obese, but otherwise healthy male and fema...
What is the current status of trial NCT01044108?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 117 participants. The study started on 2010-01-05. Estimated completion is 2011-09-20.
What interventions are being tested in trial NCT01044108?
The interventions under investigation include: placebo (DRUG), NNC 0070-0002-0453 (DRUG), '2-0453 (DRUG).
Who is sponsoring clinical trial NCT01044108?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.